Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $56.00

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $56.00.

Several research analysts have recently commented on the stock. Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday.

Agios Pharmaceuticals Stock Down 1.4%

NASDAQ:AGIO traded down $0.40 on Friday, reaching $28.74. The company's stock had a trading volume of 511,844 shares, compared to its average volume of 695,931. Agios Pharmaceuticals has a 12-month low of $23.42 and a 12-month high of $62.58. The stock has a 50 day moving average price of $29.14 and a 200 day moving average price of $37.06. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 2.53 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Equities research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. The trade was a 4.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Venturi Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. GF Fund Management CO. LTD. purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at $39,000. CWM LLC raised its stake in Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 996 shares in the last quarter. Wingate Wealth Advisors Inc. purchased a new stake in Agios Pharmaceuticals in the fourth quarter valued at $53,000. Finally, Sterling Capital Management LLC lifted its position in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after acquiring an additional 1,587 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.